Literature DB >> 35413227

Blockade of chloride channel-3 enhances cisplatin sensitivity of cholangiocarcinoma cells though inhibiting autophagy.

Yanzhen Han1, Yan Zhou2, Liyuan Zhou3, Xiaoyan Jia1, Xiangjun Yu1, Xiaohong An4, Zhe Shi1.   

Abstract

Chemotherapy is one of the most important strategies in the treatment of cancer; however, chemoresistance restricts the effect of chemotherapy. Growing reports suggest that chloride channel-3 (ClC-3) is involved in regulating the sensitivity of multiple chemotherapeutic agents in the chemotherapy of various tumours, while its role in the chemotherapy of cholangiocarcinoma (CCA) is still poorly understood. Herein, we observed that ClC-3 was highly expressed in CCA chemoresistant tissues and CCA cisplatin-resistant cells QBC939/DDP, and the sensitivities of QBC939 and QBC939/DDP cells to cisplatin were all increased after inhibition of ClC-3. Further mechanism exploration revealed that ClC-3 knockdown reduced the level of autophagy. Furthermore, in both QBC939 and QBC939/DDP cells, the autophagy agonist rapamycin eliminated the increased cisplatin sensitivity of ClC-3 knockdown without affecting ClC-3 expression. Collectively, all the findings demonstrate that ClC-3 knockdown increases cisplatin-induced cell death in CCA cells though inhibiting autophagy, regardless of the occurrence of cisplatin resistance. In addition, our results also suggest that targeted inhibition of ClC-3 may be a potential strategy for chemosensitization in CCA chemotherapy.

Entities:  

Keywords:  ClC-3; autophagie; autophagy; chemosensitivity; chimiosensibilité; cholangiocarcinoma; cholangiocarcinome; cisplatin; cisplatin resistance; cisplatine; résistance au cisplatine

Mesh:

Substances:

Year:  2022        PMID: 35413227     DOI: 10.1139/cjpp-2022-0058

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.245


  1 in total

1.  SOX2 regulates paclitaxel resistance of A549 non‑small cell lung cancer cells via promoting transcription of ClC‑3.

Authors:  Youwei Huang; Xiangyu Wang; Rendong Hu; Guopeng Pan; Xi Lin
Journal:  Oncol Rep       Date:  2022-09-07       Impact factor: 4.136

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.